<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598637</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. S02807</org_study_id>
    <nct_id>NCT00598637</nct_id>
  </id_info>
  <brief_title>Drug-eluting Stents to Treat Unprotected Coronary Left Main Disease</brief_title>
  <acronym>LEFT-MAIN-2</acronym>
  <official_title>Prospective Randomized Trial of Everolimus- and Zotarolimus-eluting Stents for Treatment of Unprotected Left Main Coronary Artery Disease: ISAR-LEFT-MAIN-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of two different drug-eluting stents
      (Everolimus and Zotarolimus-eluting) for treatment of unprotected left main coronary artery
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Restenosis in the left main coronary artery may have severe consequences given the large
      proportion of the myocardium compromised in this condition, and, in several studies, it has
      been linked to the 6-month mortality after the index procedure. Drug-eluting stents have
      reduced the restenosis rate and the need for target vessel revascularization not only in
      simple lesion but also in high risk subsets of patients and lesions such as diabetics, long
      lesions or bifurcations. There are no data about their efficacy in left main coronary artery
      disease. Thus, the aim of this study is to investigate the performance of two different
      drug-eluting stents (Everolimus and Zotarolimus-eluting) in left main coronary lesions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of major adverse cardiac event defined as a composite of death, myocardial infarction and target lesion revascularization.</measure>
    <time_frame>1 year follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic restenosis at follow-up coronary angiography.</measure>
    <time_frame>6-9 months follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">650</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>EES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus-eluting stent (Xience)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zotarolimus-eluting stent (Endeavor Resolute)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus-eluting stent (Xience)</intervention_name>
    <description>stent is implanted due to randomization</description>
    <arm_group_label>EES</arm_group_label>
    <other_name>Xience</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zotarolimus-eluting stent (Endeavor Resolute)</intervention_name>
    <description>stent is implanted due to randomization</description>
    <arm_group_label>ZES</arm_group_label>
    <other_name>Endeavor Resolute</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia
             in the presence of ≥ 50 % stenosis located in unprotected LMCA who are unable to
             undergo CABG because of cardiac surgeons' refusal (poor surgical candidates) or their
             own unwillingness.

          -  Pretreatment with a loading dose of 600 mg clopidogrel.

          -  Informed, written consent by the patients or her/his legally-authorized representative
             for participation in the study.

        Exclusion Criteria:

          -  Cardiogenic shock.

          -  ST-segment elevation acute myocardial infarction (ST-segment ≥ 0.1 mV elevation in ≥ 2
             contiguous ECG leads persisting for at least 20 minutes) within 48 hours from symptom
             onset.

          -  In-stent restenosis.

          -  Malignancies or other comorbid conditions with life expectancy less than one year or
             that may result in protocol non-compliance.

          -  Prior coronary artery bypass surgery with revascularization of LAD and/or LCx.

          -  Planned staged PCI procedure within 30 days from index procedure or prior PCI within
             the last 30 days.

          -  An elective surgical procedure is planned that would necessitate interruption of
             clopidogrel during the first six months post enrollment.

          -  Known allergy to the study medications: aspirin, clopidogrel, UHF; sirolimus,
             paclitaxel; true anaphylaxis after prior exposure to contrast media.

          -  Pregnancy (present, suspected or planned).

          -  Patient's inability to fully cooperate with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julinda Mehill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bad Segeberger Kliniken</name>
      <address>
        <city>Bad Segeberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Park SJ, Hong MK, Lee CW, Kim JJ, Song JK, Kang DH, Park SW, Mintz GS. Elective stenting of unprotected left main coronary artery stenosis: effect of debulking before stenting and intravascular ultrasound guidance. J Am Coll Cardiol. 2001 Oct;38(4):1054-60.</citation>
    <PMID>11583882</PMID>
  </reference>
  <reference>
    <citation>Park SJ, Park SW, Hong MK, Cheong SS, Lee CW, Kim JJ, Hong MK, Mintz GS, Leon MB. Stenting of unprotected left main coronary artery stenoses: immediate and late outcomes. J Am Coll Cardiol. 1998 Jan;31(1):37-42.</citation>
    <PMID>9426015</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2008</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug eluting stent</keyword>
  <keyword>left main disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

